Genzyme drug for Gaucher's disease meets trial goals
A drug for Gaucher's disease being developed by Genzyme effectively shrunk swollen spleens and livers and improved levels of hemoglobin and platelets in patients during a midstage study. At 12 months, patients who received the oral treatment GENZ-112638 showed a 39% average reduction in spleen size and a 17% average decline in liver volumes, the company reported. Boston Globe,